Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01607554 · ClinicalTrials.gov registry record · Phase 1
Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by New Mexico Cancer Research Alliance.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT01607554 is a Phase 1 study that was terminated before completion, run by New Mexico Cancer Research Alliance. The registered enrollment target is 2 participants.
The verdict
NCT01607554, a Phase 1 study, was terminated before completion, sponsored by New Mexico Cancer Research Alliance.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
Certain genetic factors can affect a patient's potential sensitivity to therapeutic drugs and other agents. There is a factor called ISG15 which might help doctors better identify patients with advanced non-small cell lung cancer (NSCLC) whose tumors may be more sensitive to the drug called Irinotecan. This factor is elevated in roughly 30% of NSCLC cases. Irinotecan is an agent that inhibits the enzyme called topoisomerase I that is involved in cell growth, and it has been FDA approved for 17 years for another type of cancer.
Interventions
- DRUG Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01607554
The ClinicalTrials.gov registry entry for NCT01607554 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Irinotecan is the first listed.
NCT01607554 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01607554 about?
NCT01607554 is a clinical study titled "Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer". Certain genetic factors can affect a patient's potential sensitivity to therapeutic drugs and other agents. There is a factor called ISG15 which might help doctors better identify patients with advanced non-small cell lung cancer (NSCLC) whose tumors may be more sensitive to the drug called Irinotec...
What is the current status of trial NCT01607554?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2012-04. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01607554?
The interventions under investigation include: Irinotecan (DRUG).
Who is sponsoring clinical trial NCT01607554?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.